Vaginal Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VGN017 MIFTS: 47	Vaginal Cancer Categories: Rare diseases, Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Vaginal Cancer

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer ¹² ⁵³ ⁴³ ¹⁵

Vaginal Neoplasms ⁴⁴ ⁷³

Vaginal Malignant Epithelial Tumor ⁵⁹

Malignant Neoplasm of Vagina ¹²

Malignant Vaginal Neoplasm ⁷³

Malignant Tumor of Vagina ¹²

Malignant Vaginal Tumor ¹²

Neoplasm of Vagina ¹²

Vaginal Carcinoma ⁵⁹

Vaginal Neoplasia ⁷³

Vaginal Neoplasm ²⁹

Vagina Carcinoma ⁷³

Vagina Neoplasm ¹²

Vaginal Tumor ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³³ ³⁴

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of vagina

Orphanet: ⁵⁹

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹² DOID:119

ICD10 ³³ C52

ICD9CM ³⁵ 184.0

MeSH ⁴⁴ D014625

NCIt ⁵⁰ C3437 C7410

SNOMED-CT ⁶⁸ 126921000 154534007 188210000 more

Orphanet ⁵⁹ ORPHA180247

UMLS via Orphanet ⁷⁴ C0262659

ICD10 via Orphanet ³⁴ C52

UMLS ⁷³ C0042237 C0042258 C0262659 more

Sources

Summaries for Vaginal Cancer

MedlinePlus : ⁴³ Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Vaginal Cancer, also known as vaginal neoplasms, is related to vaginal disease and vaginitis, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways is Antigen Presentation- Folding, assembly and peptide loading of class I MHC. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include the vagina, cervix and uterus, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : ¹² A female reproductive system cancer that is located in the vagina.

Wikipedia : ⁷⁶ Vaginal cancer is a malignant tumor that forms in the tissues of the vagina. Primary tumors are most... more...

Sources

Related Diseases for Vaginal Cancer

Diseases in the Vaginal Cancer family:

Vaginal Benign Neoplasm

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)

#	Related Disease	Score	Top Affiliating Genes
1	vaginal disease	10.9
2	vaginitis	10.7
3	cervicitis	10.2
4	malignant germ cell tumor of the vagina	10.0
5	vulvovaginal rhabdomyosarcoma	10.0
6	chylomicron retention disease	9.9	SAR1B SLC10A2
7	female reproductive organ cancer	9.8	MAPK8IP1 SMUG1
8	intrahepatic cholestasis	9.8	HLA-G SLC10A2
9	aging	9.7
10	squamous cell carcinoma	9.7
11	cervix uteri carcinoma in situ	9.7
12	cervical intraepithelial neoplasia	9.7
13	vulvar intraepithelial neoplasia	9.7
14	mayer-rokitansky-kuster-hauser syndrome	9.6
15	graft-versus-host disease	9.6
16	thrombosis	9.6
17	hydronephrosis	9.6
18	urethritis	9.6
19	chronic graft versus host disease	9.6

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Cervical Cancer
Deficiency Anemia	Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:

Sources

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:

pelvic pain, vaginal pruritus

GenomeRNAi Phenotypes related to Vaginal Cancer according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00173-A	9.32	MAPK8IP1 MYLK2
2	Decreased viability	GR00221-A-1	9.32	MYLK2
3	Decreased viability	GR00221-A-2	9.32	MYLK2
4	Decreased viability	GR00221-A-4	9.32	MAPK8IP1 MYLK2
5	Decreased viability	GR00301-A	9.32	MAPK8IP1
6	Decreased viability	GR00342-S-3	9.32	MAPK8IP1
7	Decreased viability	GR00402-S-2	9.32	MAPK8IP1 MYLK2

Sources

Drugs & Therapeutics for Vaginal Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Gardasil ¹⁸ ⁴⁹	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁸ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Octreotide

Approved, Investigational

Phase 3

83150-76-9

383414 6400441

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Granisetron

Approved, Investigational

Phase 3

109889-09-0

3510

Ondansetron

Approved

Phase 3

99614-02-5

4595

Dehydroepiandrosterone

Approved, Investigational, Nutraceutical

Phase 3

53-43-0

9860744

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Liver Extracts

Phase 3,Phase 2,Phase 1

Vaccines

Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Hormonal

Phase 3

Gastrointestinal Agents

Phase 3,Phase 1

Adjuvants, Anesthesia

Phase 3

Analgesics

Phase 3,Phase 2

Analgesics, Opioid

Phase 3

Anesthetics

Phase 3

Anesthetics, General

Phase 3

Anesthetics, Intravenous

Phase 3

Central Nervous System Depressants

Phase 3,Phase 2

Narcotics

Phase 3

Peripheral Nervous System Agents

Phase 3,Phase 2

Dermatologic Agents

Phase 3,Phase 2

Adjuvants, Immunologic

Phase 3,Phase 1

Neurotransmitter Agents

Phase 3,Phase 2

Psychotropic Drugs

Phase 3,Phase 2

Tranquilizing Agents

Phase 3,Phase 2

Anti-Anxiety Agents

Phase 3

Antiemetics

Phase 3

Antipruritics

Phase 3

Antipsychotic Agents

Phase 3

Autonomic Agents

Phase 3

Emetics

Phase 3

Serotonin Agents

Phase 3

Serotonin Antagonists

Phase 3

Cola

Nutraceutical

Phase 3,Phase 2,Phase 1

Serotonin

Investigational, Nutraceutical

Phase 3

50-67-9

5202

DHEA (Dehydroepiandrosterone)

Nutraceutical

Phase 3

Indinavir

Approved

Phase 2

150378-17-9

5362440

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Fludarabine

Approved

Phase 2,Phase 1

21679-14-1, 75607-67-9

30751

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Mycophenolate mofetil

Approved, Investigational

Phase 2

128794-94-5

5281078

Mycophenolic acid

Approved

Phase 2

24280-93-1

446541

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Aldesleukin

Approved

Phase 1, Phase 2,Phase 2

85898-30-2, 110942-02-4

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2,Phase 2

50-18-0, 6055-19-2

2907

Vidarabine

Approved, Investigational

Phase 1, Phase 2,Phase 2

24356-66-9

32326 21704

Fondaparinux

Approved, Investigational

Phase 2

104993-28-4

Bupropion

Approved

Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 2

51-61-6, 62-31-7

681

Interventional clinical trials:

(show top 50) (show all 98)

#	Name	Status	NCT ID	Phase	Drugs
1	Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer	Unknown status	NCT01087268	Phase 3
2	Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer	Completed	NCT00003267	Phase 3
3	Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)	Completed	NCT00092521	Phase 3
4	A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)	Completed	NCT01047345	Phase 3
5	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)	Completed	NCT00543543	Phase 3
6	A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)	Completed	NCT00090220	Phase 3
7	GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)	Completed	NCT01245764	Phase 3
8	Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis	Completed	NCT00033605	Phase 3	octreotide acetate
9	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
10	Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam	Recruiting	NCT03546842	Phase 3
11	Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation	Active, not recruiting	NCT01536392	Phase 3	Granisetron;Ondansetron
12	Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)	Active, not recruiting	NCT03158220	Phase 3
13	A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)	Active, not recruiting	NCT00943722	Phase 3
14	Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms	Active, not recruiting	NCT01376349	Phase 3	prasterone
15	Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer	Unknown status	NCT00905658	Phase 2
16	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
17	Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer	Completed	NCT00941070	Phase 2	triapine;cisplatin
18	Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer	Completed	NCT00002562	Phase 2	paclitaxel
19	Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer	Completed	NCT00005941	Phase 2	cyclosporine;fludarabine phosphate;mycophenolate mofetil
20	Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers	Completed	NCT00545792	Phase 2	Avastin
21	Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)	Completed	NCT00188578	Phase 1, Phase 2
22	Effectiveness of an Individualized Symptom Education Program (ISEP)	Completed	NCT00275353	Phase 2
23	T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers	Completed	NCT02280811	Phase 1, Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
24	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers	Completed	NCT01585428	Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
25	A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)	Completed	NCT00551187	Phase 2
26	Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)	Completed	NCT00520598	Phase 2	Comparator: V505 formulation 2;Comparator: V505 formulation 2
27	Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer	Completed	NCT00381888	Phase 2	fondaparinux sodium
28	Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies	Completed	NCT01079832	Phase 2
29	Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer	Completed	NCT01764802	Phase 2
30	Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer	Recruiting	NCT02466971	Phase 2	Cisplatin;Triapine
31	Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer	Recruiting	NCT01097239	Phase 1, Phase 2
32	Image-Guided Gynecologic Brachytherapy	Recruiting	NCT02993900	Phase 2
33	Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer	Recruiting	NCT03180294	Phase 2	Bupropion Hydrochloride
34	Avelumab With Valproic Acid in Virus-associated Cancer	Recruiting	NCT03357757	Phase 2	Valproic Acid
35	Image-Guided Gynecologic Brachytherapy	Active, not recruiting	NCT01399658	Phase 2
36	Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma	Not yet recruiting	NCT03220009	Phase 2
37	Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer	Terminated	NCT00106262	Phase 2	Velcade (bortezomib);Irinotecan
38	Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)	Withdrawn	NCT00365443	Phase 2
39	Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions	Unknown status	NCT00066404	Phase 1
40	Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis	Completed	NCT00002949	Phase 1	paclitaxel;vinorelbine tartrate
41	Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery	Completed	NCT00842452	Phase 1	topotecan hydrochloride
42	Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer	Completed	NCT00287885	Phase 1	docetaxel
43	Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)	Completed	NCT00851643	Phase 1
44	Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies	Completed	NCT00335998	Phase 1	triapine;cisplatin
45	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	Completed	NCT00004074	Phase 1
46	Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer	Completed	NCT01652794	Phase 1	carboplatin;gemcitabine hydrochloride
47	Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer	Completed	NCT00005842	Phase 1	tipifarnib
48	Gene Therapy in Treating Patients With Cancer	Completed	NCT00004178	Phase 1
49	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma	Completed	NCT00020579	Phase 1	entinostat
50	RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma	Completed	NCT00101972	Phase 1

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Sources

Genetic Tests for Vaginal Cancer

Genetic tests related to Vaginal Cancer:

#	Genetic test	Affiliating Genes
1	Vaginal Neoplasm ²⁹

Sources

Anatomical Context for Vaginal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Cancer:

¹⁹

The Vagina

MalaCards organs/tissues related to Vaginal Cancer:

⁴¹

Cervix, Uterus, Testes, Liver, T Cells, Brain, Prostate

Sources

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(show top 50) (show all 134)

#	Title	Authors	Year
1	Total Colpectomy Increases the Risk of Postoperative Hydronephrosis in Vaginal Cancer Patients. ( 29469636 )	Neagoe O.C....Agapie D.N.	2018
2	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. ( 29159773 )	Saito T....Katabuchi H.	2017
3	Abdominal radical trachelectomy for vaginal cancer - A case report. ( 28664182 )	Matsuoka M....Nagano T.	2017
4	Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint. ( 28796063 )	Yagi A....Kimura T.	2017
5	Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group. ( 29086206 )	Ikushima H....Toita T.	2017
6	MR Imaging of Vulvar andA Vaginal Cancer. ( 28668156 )	Shetty A.S....Menias C.O.	2017
7	Sentinel lymph node mapping with indocyanine green in vaginal cancer. ( 28541627 )	Lee I.O....Nam E.J.	2017
8	Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. ( 27486283 )	Prameela C.G....Dinesh M.	2016
9	Radical Hysterectomy and Total Abdominal Vaginectomy for Primary Vaginal Cancer. ( 26825828 )	Ozgul N....Yuce K.	2016
10	The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. ( 26790773 )	Robertson N.L....Vargas H.A.	2016
11	Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). ( 26768782 )	Chang J.H....Kim H.J.	2016
12	Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. ( 26914159 )	Akino N....Fujii T.	2016
13	Brachytherapy improves survival in primary vaginal cancer. ( 27036631 )	Orton A....Gaffney D.	2016
14	Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. ( 27327154 )	Jain V....Rawal S.	2016
15	Breast metastasis from vaginal cancer. ( 27444140 )	Chandrasekaran N....Almeida Z.	2016
16	Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. ( 26970567 )	Wolfson A.H....Gibb R.K.	2016
17	High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). ( 27010135 )	Sopracordevole F....Ciavattini A.	2016
18	Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. ( 27536721 )	Damast S....Higgins S.A.	2016
19	Outcomes with image-based interstitial brachytherapy for vaginal cancer. ( 27321150 )	Manuel M.M....Viswanathan A.N.	2016
20	Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute. ( 27430086 )	Siegler E....Lavie O.	2016
21	Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer. ( 26461231 )	Sopracordevole F....Ciavattini A.	2015
22	Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate. ( 25614068 )	Kanayama N....Ogawa K.	2015
23	Sarcoid-like reaction mimicking vaginal cancer recurrence. ( 26420533 )	Mayama M....Oguchi H.	2015
24	Management of Vaginal Cancer. ( 26411952 )	Shrivastava S....Mishra P.	2015
25	Patterns of care and brachytherapy boost utilization for vaginal cancer in the United States. ( 25413431 )	Rajagopalan M.S....Beriwal S.	2015
26	Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. ( 25966291 )	Gardner C.S....Bhosale P.R.	2015
27	Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. ( 25456026 )	Vargo J.A....Beriwal S.	2015
28	Vulval and vaginal cancer in pregnancy. ( 26526939 )	Soo-Hoo S....Luesley D.	2015
29	LASER VAPORIZATION IN VULVAR INTRAEPITHELIAL NEOPLASIA (VIN), VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN) AND CONDYLOMATA ACUMINATA: IGCS-0093 Vulvar and Vaginal Cancer. ( 25955950 )	Ramirez S....Meneses M.	2015
30	PROGNOSTIC SIGNIFICANCE OF TUMOR SIZE IN SQUAMOUS CELL CARCINOMA OF THE VULVA: IGCS-0107 Vulvar and Vaginal Cancer. ( 25955951 )	Soderini A.	2015
31	Staging for vaginal cancer. ( 25847318 )	Rajaram S....Srivastava A.	2015
32	Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. ( 24505474 )	NygAYrd M....KjA	2014
33	Successful pregnancy after uterus-sparing chemoradiation therapy for vaginal cancer. ( 25432539 )	Amsbaugh M.J....Dunlap N.E.	2014
34	HDR brachytherapy for the reirradiation of cervical and vaginal cancer: Analysis of efficacy and dosage delivered to organs at risk. ( 24161366 )	Zolciak-Siwinska A....Michalski W.	2014
35	Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer. ( 25254565 )	Sardain H....LevA-que J.	2014
36	Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. ( 24785610 )	Sinno A.K....Unger E.R.	2014
37	Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. ( 24423603 )	Strander B....SparAcn P.	2014
38	Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. ( 25319982 )	Feldbaum V.M....Oprea-Ilies G.M.	2014
39	Vaginal cancer in a patient with complicated prolapse history: a case report. ( 25181382 )	Leadley S....Brincat C.A.	2014
40	Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: A National Cancer Data Base (NCDB) study. ( 25281493 )	Rajagopalan M.S....Beriwal S.	2014
41	Uterine prolapse complicated by vaginal cancer: a case report and literature review. ( 24481208 )	Wang Y....Liu H.	2014
42	Acr appropriateness Criteria management of vaginal cancer. ( 24575547 )	Lee L.J....Gaffney D.K.	2013
43	A case of vaginal cancer with uterine prolapse. ( 25371880 )	Kim H.G....Choi O.H.	2013
44	Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? ( 23212765 )	Baiocchi G....Lopes A.	2013
45	Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy. ( 24080298 )	Kim H....Beriwal S.	2013
46	Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer. ( 23453679 )	Rajagopalan M.S....Beriwal S.	2013
47	Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. ( 24396823 )	Kim J.Y....Lee J.W.	2013
48	HLA-G 3'UTR polymorphisms in high grade and invasive cervico-vaginal cancer. ( 23228396 )	Silva I.D....SimA/es R.T.	2013
49	Is there a place for sentinel technique in treatment of vaginal cancer?: feasibility, clinical experience, and results. ( 24177255 )	Hertel H....Hillemanns P.	2013
50	Concurrent chemoradiation for vaginal cancer. ( 23762284 )	Miyamoto D.T....Viswanathan A.N.	2013

Sources

Genes for Vaginal Cancer

Genes related to Vaginal Cancer (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HLA-G	Major Histocompatibility Complex, Class I, G	Protein Coding	20.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	SLC10A2	Solute Carrier Family 10 Member 2	Protein Coding	16.4	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
3	MYLK2	Myosin Light Chain Kinase 2	Protein Coding	15.59	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	MAPK8IP1	Mitogen-Activated Protein Kinase 8 Interacting Protein 1	Protein Coding	15.52	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	SMUG1	Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1	Protein Coding	15.26	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	HPD	4-Hydroxyphenylpyruvate Dioxygenase	Protein Coding	15.14	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
7	LRIG2	Leucine Rich Repeats And Immunoglobulin Like Domains 2	Protein Coding	15.09	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	EIF4A3	Eukaryotic Translation Initiation Factor 4A3	Protein Coding	15	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
9	SAR1B	Secretion Associated Ras Related GTPase 1B	Protein Coding	14.99	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Vaginal Cancer

Cosmic variations for Vaginal Cancer:

⁹

(show top 50) (show all 187)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM6933523	STAT3	vagina,NS,carcinoma,squamous cell carcinoma	c.1110-2A>G	p.?	17:42329778-42329778	12
2	COSM6968882	PTPRT	vagina,NS,carcinoma,squamous cell carcinoma	c.3418G>A	p.E1140K	20:42106824-42106824	12
3	COSM6968877	NSD1	vagina,NS,carcinoma,squamous cell carcinoma	c.5717G>T	p.G1906V	5:177280659-177280659	12
4	COSM6448770	NFKBIA	vagina,NS,carcinoma,squamous cell carcinoma	c.127G>C	p.E43Q	14:35404518-35404518	12
5	COSM6968885	EIF1AX	vagina,NS,carcinoma,squamous cell carcinoma	c.415G>T	p.E139*	23:20130530-20130530	12
6	COSM6968886	EIF1AX	vagina,NS,carcinoma,squamous cell carcinoma	c.64G>C	p.E22Q	23:20138575-20138575	12
7	COSM6968884	AURKA	vagina,NS,carcinoma,squamous cell carcinoma	c.127C>T	p.Q43*	20:56386449-56386449	12
8	COSM6968887	ATRX	vagina,NS,carcinoma,squamous cell carcinoma	c.4498G>A	p.E1500K	23:77652173-77652173	12
9	COSM6968883		vagina,NS,carcinoma,squamous cell carcinoma	c.3382G>A	p.E1128K	20:42106824-42106824	12
10	COSM6448769		vagina,NS,carcinoma,squamous cell carcinoma	c.127G>C	p.E43Q	14:35404518-35404518	12
11	COSM125370		vagina,NS,carcinoma,squamous cell carcinoma	c.1633G>A	p.E545K	3:179218303-179218303	12
12	COSM6968878		vagina,NS,carcinoma,squamous cell carcinoma	c.5717G>T	p.G1906V	5:177280659-177280659	12
13	COSM6968888		vagina,NS,carcinoma,squamous cell carcinoma	c.4498G>A	p.E1500K	23:77652173-77652173	12
14	COSM6917051	TSC2	cervix,NS,carcinoma,squamous cell carcinoma	c.4975C>G	p.L1659V	16:2086857-2086857	5
15	COSM43662	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.868C>A	p.R290S	17:7673752-7673752	5
16	COSM44029	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.550G>A	p.D184N	17:7675062-7675062	5
17	COSM10705	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.586C>T	p.R196*	17:7674945-7674945	5
18	COSM10648	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.524G>A	p.R175H	17:7675088-7675088	5
19	COSM45507	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.806G>C	p.S269T	17:7673814-7673814	5
20	COSM43660	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.719G>T	p.S240I	17:7674244-7674244	5
21	COSM10725	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.701A>G	p.Y234C	17:7674262-7674262	5
22	COSM46185	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.775G>C	p.D259H	17:7674188-7674188	5
23	COSM10889	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.536A>G	p.H179R	17:7675076-7675076	5
24	COSM10662	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.743G>A	p.R248Q	17:7674220-7674220	5
25	COSM43878	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.427G>A	p.V143M	17:7675185-7675185	5
26	COSM43624	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.875A>G	p.K292R	17:7673745-7673745	5
27	COSM10659	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.817C>T	p.R273C	17:7673803-7673803	5
28	COSM43896	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.818G>C	p.R273P	17:7673802-7673802	5
29	COSM10749	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.830G>T	p.C277F	17:7673790-7673790	5
30	COSM45259	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.301A>T	p.K101*	17:7676068-7676068	5
31	COSM11483	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.848G>A	p.R283H	17:7673772-7673772	5
32	COSM11356	TP53	cervix,NS,carcinoma,squamous cell carcinoma	c.726C>G	p.C242W	17:7674237-7674237	5
33	COSM6917055	TOP1	cervix,NS,carcinoma,squamous cell carcinoma	c.1897C>T	p.Q633*	20:41118243-41118243	5
34	COSM6933657	TGFBR2	cervix,NS,carcinoma,squamous cell carcinoma	c.931G>T	p.E311*	3:30672114-30672114	5
35	COSM6918339	TET2	cervix,NS,carcinoma,squamous cell carcinoma	c.2659G>A	p.E887K	4:105236601-105236601	5
36	COSM6906292	TENT5C	cervix,NS,carcinoma,squamous cell carcinoma	c.722G>T	p.G241V	1:117623590-117623590	5
37	COSM25844	STK11	cervix,NS,carcinoma,squamous cell carcinoma	c.647C>T	p.S216F	19:1220630-1220630	5
38	COSM29465	STK11	cervix,NS,carcinoma,squamous cell carcinoma	c.320A>G	p.H107R	19:1218446-1218446	5
39	COSM3734673	STK11	cervix,NS,carcinoma,squamous cell carcinoma	c.597G>C	p.E199D	19:1220505-1220505	5
40	COSM29464	STK11	cervix,NS,carcinoma,squamous cell carcinoma	c.169G>T	p.E57*	19:1207082-1207082	5
41	COSM6977087	SPOP	cervix,NS,carcinoma,squamous cell carcinoma	c.962C>T	p.A321V	17:49601883-49601883	5
42	COSM421102	ROS1	cervix,NS,carcinoma,squamous cell carcinoma	c.1682C>T	p.P561L	6:117389427-117389427	5
43	COSM6977085	RB1	cervix,NS,carcinoma,squamous cell carcinoma	c.1630A>T	p.R544*	13:48381378-48381378	5
44	COSM6910533	RAD54L	cervix,NS,carcinoma,squamous cell carcinoma	c.1900C>T	p.R634C	1:46277847-46277847	5
45	COSM6977079	RAD50	cervix,NS,carcinoma,squamous cell carcinoma	c.432G>C	p.E144D	5:132587654-132587654	5
46	COSM6977082	RAD21	cervix,NS,carcinoma,squamous cell carcinoma	c.1702C>T	p.Q568*	8:116848948-116848948	5
47	COSM6977083	RAD21	cervix,NS,carcinoma,squamous cell carcinoma	c.1681C>T	p.Q561*	8:116848969-116848969	5
48	COSM6975050	PTPRS	cervix,NS,carcinoma,squamous cell carcinoma	c.5630C>G	p.S1877C	19:5208249-5208249	5
49	COSM6917045	PTPRD	cervix,NS,carcinoma,squamous cell carcinoma	c.1693G>A	p.E565K	9:8504390-8504390	5
50	COSM5089	PTEN	cervix,NS,carcinoma,squamous cell carcinoma	c.517C>T	p.R173C	10:87952142-87952142	5

Sources

Expression for Vaginal Cancer

Search GEO for disease gene expression data for Vaginal Cancer.

Sources

Pathways for Vaginal Cancer

Pathways related to Vaginal Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Antigen Presentation- Folding, assembly and peptide loading of class I MHC ⁶⁶	10.02	HLA-G SAR1B

Sources

GO Terms for Vaginal Cancer

Cellular components related to Vaginal Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ER to Golgi transport vesicle membrane	GO:0012507	8.62	HLA-G SAR1B

Biological processes related to Vaginal Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	antigen processing and presentation of peptide antigen via MHC class I	GO:0002474	8.62	HLA-G SAR1B

Sources

Sources for Vaginal Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia